Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and TELA Bio (NASDAQ:TELA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.
Institutional and Insider Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of TELA Bio shares are owned by institutional investors. 9.6% of Vivos Therapeutics shares are owned by insiders. Comparatively, 5.7% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Vivos Therapeutics and TELA Bio’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $13.80 million | 0.53 | -$13.58 million | ($11.05) | -0.24 |
| TELA Bio | $58.45 million | 2.18 | -$46.66 million | ($2.07) | -2.50 |
Profitability
This table compares Vivos Therapeutics and TELA Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -98.42% | -665.17% | -122.48% |
| TELA Bio | -79.83% | -201.62% | -58.60% |
Risk and Volatility
Vivos Therapeutics has a beta of 7.94, suggesting that its share price is 694% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Vivos Therapeutics and TELA Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 0 | 0 | 0 | 0 | N/A |
| TELA Bio | 0 | 0 | 3 | 0 | 3.00 |
TELA Bio has a consensus price target of $13.67, suggesting a potential upside of 164.35%. Given TELA Bio’s higher possible upside, analysts plainly believe TELA Bio is more favorable than Vivos Therapeutics.
Summary
TELA Bio beats Vivos Therapeutics on 9 of the 13 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
About TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
